A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT05488314
- Locations
- π°π·
Gachon University Gil Hospital, Incheon, Korea, Republic of
π°π·Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of
π°π·Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05463939
A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05461209
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
π΅π±Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, Poland
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Drug: AticaprantOther: Placebo
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 513
- Registration Number
- NCT05455684
- Locations
- π¨πΏ
Narodni ustav dusevniho zdravi, Klecany, Czechia
π¨πΏPraglandia s r o, Prague 5, Czechia
π¨πΏClintrial s r o, Praha 10, Czechia
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 810
- Registration Number
- NCT05455320
- Locations
- πΊπΈ
University of Kansas, Westwood, Kansas, United States
πΊπΈThe Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States
πΊπΈOhioHealth, Columbus, Ohio, United States
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- π«π·
Chu Rennes Hopital Pontchaillou, Rennes Cedex 9, France
πΊπΈThe University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈCity of Hope, Duarte, California, United States
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- Biological: VAC85135Drug: Ipilimumab
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05444530
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
π¬π§Churchill Hospital, Oxford, United Kingdom
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: JNJ-80038114
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT05441501
- Locations
- π¬π§
Royal Marsden Hospital, Sutton, United Kingdom
πΊπΈUniversity Of Minnesota, Minneapolis, Minnesota, United States
πΊπΈSidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
A Study of Daratumumab
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05438043
- Locations
- πΊπΈ
University of Miami Sylvester Cancer Center, Miami, Florida, United States
πΊπΈBarnes-jewish Hospital, Saint Louis, Missouri, United States
π§πͺZNA Stuivenberg, Antwerpen, Belgium
A Single and Multiple Ascending Dose Study of JNJ-64457744
- Conditions
- Hepatitis B, ChronicHealthy
- Interventions
- Drug: JNJ-64457744Drug: PlaceboDrug: Tenofovir Disoproxil Fumarate (TDF)Drug: Tenofovir Alafenamide (TAF)Drug: Entecavir (ETV)
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05423106
- Locations
- π³πΏ
New Zealand Clinical Research, Grafton, New Zealand